Gascoyne Randy D, Lamant Laurence, Martin-Subero Jose I, Lestou Valia S, Harris Nancy Lee, Müller-Hermelink Hans-Konrad, Seymour John F, Campbell Lynda J, Horsman Douglas E, Auvigne Isabelle, Espinos Estelle, Siebert Reiner, Delsol Georges
Department of Oncogeneiss and Signaling in Hematopoietic Cells, Instiut National de la Santé et de la Recherche Médicale U-563, Centre de Physiopatholgie de Toulouse-Purpan, France.
Blood. 2003 Oct 1;102(7):2568-73. doi: 10.1182/blood-2003-03-0786. Epub 2003 May 22.
Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL). All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners. A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL. However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive. We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23. All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with standard cytogenetic analysis, multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction. These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression. Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases associated with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.
淋巴细胞中ALK蛋白的表达以及变异型间变性淋巴瘤激酶(ALK)易位的描述通常局限于T细胞和裸细胞间变性大细胞淋巴瘤(ALCL)病例。所有这些病例均源于2号染色体2p23上的ALK基因与5号染色体5q35上的NPM或其他变异易位伙伴产生的新型融合。一种罕见的弥漫性大B细胞淋巴瘤(DLBCL)变异型最初于1997年被描述,与ALCL特征性的嵌合蛋白不同,该变异型被认为过度表达全长ALK。然而,全长ALK蛋白缺乏酪氨酸激酶活性,因此肿瘤发生机制仍不清楚。我们描述了6例ALK阳性DLBCL病例,其特征为简单或复杂的t(2;17)(p23;q23),涉及17号染色体带17q23上的网格蛋白基因(CLTC)和2号染色体带2p23上的ALK基因。所有病例均采用荧光原位杂交(FISH)进行研究,其中1例辅以标准细胞遗传学分析、多色核型分析(M-FISH)和逆转录聚合酶链反应。这些结果清楚地表明,大多数ALK阳性DLBCL病例具有相同的ALK表达失调机制。此外,这些结果证明了这些肿瘤中存在CLTC-ALK融合,并将与这种基因异常相关的疾病列表扩展到包括经典T细胞或裸细胞ALCL、ALK阳性DLBCL和炎性肌纤维母细胞瘤。